Phase 3 Readout
TVTX: Phase 3 Topline: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Sa
July 1, 2026 · sparsentan. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 1, 2026
- Company
- Travere Therapeutics, Inc. (TVTX)
- Drug
- sparsentan
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Sa
- Drug
- sparsentan
- Indication
- Immunoglobulin A Nephropathy